Provided by Tiger Trade Technology Pte. Ltd.

Sangamo Therapeutics Inc

0.2620
-0.0080-2.96%
Post-market: 0.27520.0132+5.04%18:32 EDT
Volume:3.12M
Turnover:855.64K
Market Cap:108.47M
PE:-0.60
High:0.2840
Open:0.2759
Low:0.2620
Close:0.2700
52wk High:0.8400
52wk Low:0.2050
Shares:414.00M
Float Shares:364.00M
Volume Ratio:0.61
T/O Rate:0.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4400
EPS(LYR):-0.4400
ROE:-2891.84%
ROA:-83.66%
PB:-7.60
PE(LYR):-0.60

Loading ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Terns Pharmaceuticals (TERN), Sangamo Therapeutics (SGMO) and Galectin Therapeutics (GALT)

TIPRANKS
·
Mar 31

Sangamo Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 31

Sangamo reports Q4 EPS (11c), consensus (5c)

TIPRANKS
·
Mar 31

Sangamo publishes corporate presentation highlighting neurology genomic medicines pipeline, Fabry BLA progress

Reuters
·
Mar 31

Sangamo Q4 revenue misses analyst expectations

Reuters
·
Mar 31

Sangamo FY25 net loss widens to $123 million; revenue drops to $40 million

Reuters
·
Mar 31

BRIEF-Sangamo Therapeutics Q4 EPS USD -0.11

Reuters
·
Mar 31

Sangamo Therapeutics Q4 Revenue USD 14.228 Million

THOMSON REUTERS
·
Mar 31

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

THOMSON REUTERS
·
Mar 31

Sangamo options imply 27.2% move in share price post-earnings

TIPRANKS
·
Mar 31

Options Volatility and Implied Earnings Moves Today, March 30, 2026

TIPRANKS
·
Mar 30

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 30

Sangamo Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview

Reuters
·
Mar 28

Sangamo Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview

Reuters
·
Mar 21

Sangamo Therapeutics schedules fourth-quarter and full-year 2025 earnings call

Reuters
·
Mar 20

Sangamo Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview

Reuters
·
Mar 14

Sangamo submits ST-920 BLA clinical and preclinical modules to FDA for Fabry disease accelerated approval review

Reuters
·
Mar 09

Sangamo Therapeutics Advances Rolling Submission of Bla to U.S. FDA for St-920 in Fabry Disease

THOMSON REUTERS
·
Mar 09

Sangamo Therapeutics: STAAR Study Demonstrated Positive Mean Annualized Egfr Slope at 52-Weeks Across All Dosed Patients

THOMSON REUTERS
·
Mar 09

What Sangamo Therapeutics (SGMO)'s Fabry Gene Therapy Progress And Equity Raise Means For Shareholders

Simply Wall St.
·
Feb 04